Myelosuppressive chemotherapy is frequently used for mobilization of autologous CD34
The two most commonly used myeloid growth factors for facilitation of peripheral blood stem cell (PBSC) harvests in the USA are recombinant human granulocyte colonystimulating factor (rHuG-CSF; filgrastim) [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] and recombinant human granulocyte-macrophage colony-stimulating factor (rHuGM-CSF; sargramostim). Sargramostim is a glycosylated form of rHuGM-CSF derived from yeast and marketed in the USA [12] [13] [14] [15] and molgramostim is an unglycosylated form of rHuGM-CSF derived from Escherichia coli and only available for experimental use in the USA. [16] [17] [18] [19] [20] [21] [22] [23] [24] It has not been determined in randomized prospective trials whether there are major differences between myeloid growth factor regimens and CD34
+ cell yields and morbidity following myelosuppressive chemotherapy (MC). There are reports of harvesting PBSC with MC followed by filgrastim, [4] [5] [6] [7] [8] [9] [10] [11] 25 sargramostim 14, 15, 26 or the combination of sargramostim and filgrastim, 12 but there have been no prospective, randomized studies comparing relative effectiveness. A prospective randomized trial was performed to compare the effects of filgrastim alone, sargramostim alone, or the sequential administration of sargramostim and filgrastim on CD34
+ cell yields, hematological recovery, morbidity, and resource utilization after the administration of MC.
Patients and methods
This was a randomized, open-label trial of three schedules of myeloid growth factors administered after MC for the collection of CD34
+ PBSC. The MC regimen -cyclophos-phamide and etoposide (CE) or paclitaxel and cyclophosphamide (PC) -was determined by the primary treatment protocol. The following three groups of patients were evaluated: (1) filgrastim alone: daily administration until PBSC harvests were completed; (2) sargramostim alone: daily administration until PBSC harvests were completed; (3) sargramostim followed by filgrastim: daily administration of sargramostim for 5 days followed by daily filgrastim until PBSC harvests were completed. One hundred and fifty-six patients were evaluable for toxicity of MC, 150 were evaluable for efficiency of PBSC harvests, and 126 were evaluable for engraftment parameters after a single course of high-dose chemotherapy (HDC) and PBSC infusion.
Patients were treated in one of 39 medical centers in the USA under the care of 88 medical oncologists affiliated with the Clinical Trials Division of Response Oncology, Inc. (ROI), Memphis, TN. 27 Chemotherapy for all phases of treatment was administered and PBSC harvested in an outpatient facility. Patients who required admission were admitted to hospitals meeting the criteria of the American Society of Clinical Oncology/American Society of Hematology Guidelines for Stem Cell Transplantation. ) on day 2 (PC, n = 81). 29 Myeloid growth factor administration was begun on the day after the completion of MC. The regimens evaluated were: filgrastim 6 g/kg/day (Amgen, Thousand Oaks, CA, USA), sargramostim 250 g/m 2 /day (Immunex, Seattle, WA, USA), or sargramostim 250 g/m 2 /day for 5 days followed by filgrastim 6 g/kg/day. All myeloid growth factors were administered daily until the final day of apheresis. 29 The following HDC regimens were administered to 126 patients: cyclophosphamide, thiotepa, and carboplatin (CTCb, n = 87), 27 carmustine, etoposide, cytarabine, and cyclophosphamide (BEAC, n = 25), 30 busulfan, melphalan, and thiotepa (BuMelTT, n = 13), 31 or a single high dose of melphalan (n = 1). 32 All patients received filgrastim 6 g/kg/day beginning on day 1 after PBSC infusion and continuing until the absolute neutrophil count (ANC) was Ͼ0.5 ϫ 10 9 /l for 3 consecutive days. The optimal dose for support of HDC was considered to be у5.0 ϫ 10 6 CD34 + cells/kg and the minimal dose to proceed with HDC was 1.0 ϫ 10 6 CD34 + cells/kg. 33 Patients who yielded Ͻ2.5 but Ͼ1.0 ϫ 10 6 CD34 + cells/kg could elect to have HDC supported by less than optimal CD34 + cell numbers or undergo a second mobilization procedure. 34 Patients received MC and HDC in an outpatient treatment facility with daily surveillance for complications warranting hospital admission. 35 
Results
Characteristics of the 156 evaluable patients receiving MC are shown in Table 1 . There were no statistically significant differences between the three groups.
Hematopoietic recovery and resource utilization
The effects of growth factor regimen on hematopoietic recovery and resource utilization after MC are shown in Table 2 . Four patients died of treatment-related causes 9 to 15 days after the first dose of MC without recovery of neutrophils or platelets (infection = 2, multi-organ failure = 2).
CD34
+ cell harvests and growth factor administration
The median number of CD34 + cells collected for all 150 patients was 8.5 × 10 6 /kg (range, 0.02 to 96) in a median of two aphereses (range, 1 to 9), with a median of 13 days of growth factor administration (range, 9 to 22). The results of CD34
+ cell yields for the three groups of patients are shown in Table 3 .
+ cell yields following PC or CE Tables 4 and 5 summarize the differences observed in CD34 + cell harvests between patients receiving MC consisting of PC or CE.
Hematological recovery following HDC
Treatment regimens, hematological recovery, and resource utilization after HDC are shown in Table 6 .
Discussion
A major finding in this study was that patients receiving filgrastim after MC yielded more CD34
+ cells than patients receiving sargramostim. There were differences in CD34 + cell yields between the two MC regimens as shown in Tables 4 and 5 . Twice as many CD34
+ cells were collected following CE as following PC. For patients receiving CE, more CD34
+ cells were collected following filgrastim alone or sequential sargramostim and filgrastim than following sargramostim alone. However, 82% of patients receiving sargramostim yielded у2.5 ϫ 10 6 CD34 + cells/kg and 77% yielded у5.0 ϫ 10 6 CD34 + cells/kg, which was not significantly different than patients receiving filgrastim alone or sequential sargramostim and filgrastim (Table 4) . Thus, sargramostim and filgrastim following CE were equally effective for achieving target CD34
+ cell numbers. The major differences in achieving target CD34
+ cell yields were observed in patients receiving PC (Table 5 ). In general, PC was associated with less toxicities and more rapid hematological recovery than CE. It has been previously observed that more intensive chemotherapy regimens are associated with a better CD34 + cell yield than less intensive regimens; this would probably explain the current observations. 1, 5, 36 There have been no previous randomized trials comparing the prophylactic administration of filgrastim to sargramostim after MC. However, one randomized trial compared filgrastim to molgramostim in 26 patients with Hodgkin's disease receiving MC. 16 Twenty-one patients completed PBSC collections and there were no differences in CD34 + cell yields or toxicities between the two groups. 16 Bregni et al, 18 in a non-randomized trial, compared filgrastim to molgramostim administered by continuous intravenous infusion in 49 patients with malignant lymphoma receiving cyclophosphamide 7 g/m 2 . 18 These investigators found more rapid recovery of neutrophils following filgrastim (P = 0.01), more rapid recovery of platelets following molgramostim (P = 0.01), and more CD34 + cells/kg/apheresis following molgramostim (the latter difference not being statistically significant, P = 0.132). 18 This study also found no differences in yields of undifferentiated hematopoietic progenitors as defined by the CD34 + /CD33 − surface phenotype. 18 Differences between these two studies and the current study could be due to differences in the rHuGM-CSF molecule, in the myelosuppressive regimens, in dose and Bone Marrow Transplantation schedule of growth factor administration, or to the relatively small number of patients evaluated. 16, 18 Filgrastim has been compared to sargramostim or the combination of sargramostim and filgrastim in normal individuals. 13, [37] [38] [39] These studies demonstrated that filgrastim alone or sequential sargramostim and filgrastim mobilized more CD34
S25
+ cells than sargramostim alone in normal persons. 13, [37] [38] [39] These studies also suggested that sequential sargramostim and filgrastim mobilized more primitive hematopoietic cells (CD23 + /CD38 − /HLA-DR + ) than either drug alone. 13, [37] [38] [39] The practical significance of these observations for PBSC transplantation is unknown. However, the lack of reports of late graft failure following autologous or allogeneic transplantation with filgrastim-mobilized PBSC Table 3 Results of CD34 + cell harvests and growth factor administration (n = 150) 
Table 4
Results of CD34 + cell harvests and growth factor administration after cyclophosphamide and etoposide (n = 70) 
Table 5
Results of CD34 + cell harvests and growth factor administration after paclitaxel and cyclophosphamide (n = 80) Table 6 Hematopoietic recovery and resource utilization after high-dose chemotherapy (n = 126) suggests that the infusion of inadequate quantities of more primitive stem cells is not a major clinical problem. Spitzer et al 12 randomized patients to receive filgrastim 10 g/kg/day or the combination of filgrastim 10 g/kg/day plus sargramostim 5 g/kg/day without prior chemotherapy and found no increase in CD34 + cell yields following the combination growth factor administration. These observations are consistent with those of the current study, although the schedule of growth factor administration was concurrent rather than sequential as in the present study.
In the present study, hematopoietic recovery after a single course of HDC and PBSC infusion was evaluated in 126 patients (Table 6) . Patients who had PBSC mobilized with CE or PC and sargramostim alone received 50% less CD34
+ cells compared to patients receiving cells harvested after filgrastim or sequential sargramostim and filgrastim. There was a faster recovery by 3 days of platelets in patients receiving filgrastim-mobilized PBSC than in patients receiving sargramostim-mobilized PBSC (day 9 vs day 12, P = 0.015), which was probably due to the large difference in median CD34
+ cell dose. This finding lends further support to a number of studies which have shown that infusing у5.0 ϫ 10 6 CD34 + cells/kg is associated with a reduction in time to platelet recovery and less supportive care requirements. 6, 29, 40, 41 Patients receiving sequential sargramostim and filgrastim-mobilized PBSC did not recover platelets until a median of day 11 compared to day 9 for patients receiving comparable median numbers of filgrastim-mobilized CD34
+ cells (P = 0.101). However, this was probably due to the fact that 29% of patients infused with PBSC mobilized by sequential sargramostim and filgrastim were transfused with Ͻ5 ϫ 10 6 CD34 + cells/kg compared
Bone Marrow Transplantation to 14% for patients infused with PBSC mobilized with filgrastim alone (P = 0.087). As shown in Table 2 , patients receiving filgrastim or the sequential regimen had a faster recovery of neutrophils to 0.5 ϫ 10 9 /l compared to patients receiving sargramostim alone (P = 0.0001 and 0.0001, respectively). The increased incidence of fever in patients receiving sargramostim probably accounts for the increased frequency of hospital admissions and intravenous antibiotic usage. Fever in the sargramostim group was most likely due to the drug itself and not to infection since the incidence of documented bacteremia was the same for all three groups.
The higher incidence of anemia and more frequent red blood cell transfusions in the sargramostim group was an unexpected finding as neither filgrastim or sargramostim have a known effect on red blood cell production. The mechanism by which sargramostim-treated patients developed more anemia than patients receiving filgrastim or the sequential regimen was not investigated and could only be speculated upon. There were no differences in the frequency of patients with a platelet nadir among the three groups. More patients in the sargramostim group received platelet transfusions than patients receiving filgrastim or the sequential regimen, but these differences did not reach statistical significance.
The current findings are, in general, consistent with the studies of myeloid growth factors alone (ie without chemotherapy) for mobilization of PBSC. 12, 13, [37] [38] [39] If the goal is to harvest large quantities of CD34 + cells with the least morbidity and resource utilization, filgrastim alone administered after MC would appear to be the best currently available myeloid growth factor regimen. Other potential benefits of mobilizing PBSC with sargramostim or sequential sargramostim and filgrastim (ie possible mobilization of more primitive stem cells or dendritic cells) were not addressed in this study. 13, [37] [38] [39] 
